A detailed history of Crewe Advisors LLC transactions in Biogen Inc. stock. As of the latest transaction made, Crewe Advisors LLC holds 20 shares of BIIB stock, worth $2,929. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20
Previous 20 -0.0%
Holding current value
$2,929
Previous $4,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$212.02 - $267.71 $4,240 - $5,354
20 New
20 $4,000
Q2 2023

Jul 28, 2023

BUY
$275.25 - $318.06 $550 - $636
2 New
2 $0
Q3 2022

Nov 14, 2022

BUY
$194.69 - $268.46 $1,752 - $2,416
9 Added 50.0%
27 $7,000
Q2 2022

Aug 02, 2022

BUY
$187.54 - $223.02 $3,375 - $4,014
18 New
18 $4,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Crewe Advisors LLC Portfolio

Follow Crewe Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crewe Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Crewe Advisors LLC with notifications on news.